Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167913 | 1.00 | CES2 (0.61) | CES2CES1PTPN1GSK3BPARP1 | |
| SCHEMBL9409741 | 0.85 | GSK3B (0.70) | CES1PTPN1GSK3BKDM4EMAPT | |
| SCHEMBL29987428 | 0.83 | MEN1 (0.72) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL3712920 | 0.82 | CES2 (0.63) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL364308 | 0.82 | CES2 (0.63) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL29368006 | 0.82 | CES2 (0.63) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL29772245 | 0.82 | CES2 (0.63) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL7387888 | 0.80 | MAPT (0.52) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL2294919 | 0.80 | PARP1 (0.62) | CES2CES1PARP1KDM4EMAPT | |
| SCHEMBL13785097 | 0.80 | CES2 (0.61) | CES2CES1PARP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116262673-B | Preparation method of alpha-bromoacetophenone compound | 浙江工业大学 | 2025-04-29 | — | — | CN | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| CN-119119027-A | Azetidine derivative and preparation method and application thereof | 遵义医科大学 | 2024-12-13 | — | — | CN | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| CN-117105853-A | 3-hydroxypyridine-4 (H) -ketone derivative, and preparation method and application thereof | 浙江工业大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-116262673-A | Preparation method of alpha-bromoacetophenone compound | 浙江工业大学 | 2023-06-16 | — | — | CN | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022188876-A1 | FUSED RING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | 浙江大学 | 2022-09-15 | — | — | WO | disclosed |
| CN-109153649-B | Allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CES2 3468/4885CES1 1403/4885PTPN1 1527/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CES2 3468/4885CES1 1403/4885PTPN1 1527/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | CES2 3468/4885CES1 1403/4885PTPN1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.